Connect with us

Business

FDA Adviser Quits Over ‘Probably The Worst’ Approval Decision Of Alzheimer’s Drug – HuffPost

The controversial drug, called Aduhelm, costs $56,000 a year and some patients could face copayments of $11,500 annually.

Published

on

Article feature image
ADVERTISEMENT

WASHINGTON (AP) A new $56,000-a-year Alzheimers drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.
The drug,…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Major investors reportedly up stakes in Stripe ahead of public listing – CNBC
Article feature image
Bank of America CEO details back-to-office plan, concentrating on Covid-vaccinated employees first – CNBC
Article feature image
Off-duty flight attendant allegedly choked a crew member and claimed to be seated next to a terrorist before being subdued, police report says – CNN